BiotechTube

Abemaciclib + Temozolomide

Phase 2Active
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glioma

Conditions

Glioma

Trial Timeline

Oct 25, 2024 → Feb 1, 2028

NCT ID
NCT06413706

About Abemaciclib + Temozolomide

Abemaciclib + Temozolomide is a phase 2 stage product being developed by Eli Lilly for Glioma. The current trial status is active. This product is registered under clinical trial identifier NCT06413706. Target conditions include Glioma.

What happened to similar drugs?

0 of 3 similar drugs in Glioma were approved

Approved (0) Terminated (0) Active (3)
🔄Everolimus + ONC201Jazz PharmaceuticalsPhase 3
🔄Tovorafenib + Chemotherapeutic AgentDay One BiopharmaceuticalsPhase 3
🔄safusidenib + PlaceboNuvation BioPhase 3

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06413706Phase 2Active

Competing Products

20 competing products in Glioma

See all competitors
ProductCompanyStageHype Score
TemozolomideNovocurePhase 1
15
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
29
LY2157299 + LomustineEli LillyPhase 1
29
DS-1001bDaiichi SankyoPhase 2
39
DS-1001bDaiichi SankyoPhase 1
33
Perampanel + Standard of CareEisaiPhase 1/2
32
Temozolomide and BevacizumabEisaiPhase 2
31
TemozolomideEisaiPhase 2
31
Gliadel Wafer + TemozolomideEisaiPhase 2
31
Palonosetron (PALO)EisaiPhase 2
35
Gliadel/Avastin/CPT-11EisaiPhase 2
27
Lenvatinib + BevacizumabEisaiPhase 2
35
Granisetron + OndansetronKyowa KirinPhase 2
27
Binimetinib 15 MGOno PharmaceuticalPhase 2
42
EnzastaurinEli LillyPhase 2
35
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
21
LY2157299 + Radiation + TemozolomideEli LillyPhase 1/2
32
DSP-0390Sumitomo PharmaPhase 1
36
DSP-0390Sumitomo PharmaPhase 1
33
ApatinibJiangsu Hengrui MedicinePhase 2
31